rBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma.,FEBS Open Bio

当前位置： X-MOL 学术 › FEBS Open Bio › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

rBC2LCN lectin as a potential probe of early-stage HER2-positive breast carcinoma.
FEBS Open Bio ( IF 2.8 ) Pub Date : 2020-05-05 , DOI: 10.1002/2211-5463.12852
Shuuji Mawaribuchi ₁ , Yoshikazu Haramoto ₁ , Hiroaki Tateno ₁ , Yasuko Onuma ₁ , Yasuhiko Aiki ₁ , Yuzuru Ito ₁

Affiliation

The recombinant N‐terminal domain of BC2L‐C lectin (rBC2LCN) is useful for detecting not only human pluripotent stem cells but also some cancers. However, the cancer types and stages that can be detected by rBC2LCN remain unclear. In this study, we identified the human breast carcinoma subtypes and stages that can be detected by rBC2LCN. Compared with rBC2LCN‐negative breast carcinoma cell lines, the rBC2LCN‐positive cells expressed higher levels of human epidermal growth factor receptor 2 (HER2) and epithelial marker genes. Importantly, rBC2LCN histochemical staining of human breast carcinoma tissues demonstrated the utility of rBC2LCN in detecting breast carcinoma types that express HER2 and have not spread much in the early phase of growth. We conclude that rBC2LCN may have potential as a detection probe and a drug delivery vehicle to identify and treat early‐stage HER2‐positive breast carcinoma.

中文翻译：

rBC2LCN凝集素可作为早期HER2阳性乳腺癌的潜在探针。

BC2L-C凝集素（rBC2LCN）的重组N末端结构域不仅可用于检测人多能干细胞，还可用于检测某些癌症。然而，尚不清楚rBC2LCN可以检测到的癌症类型和分期。在这项研究中，我们确定了可以通过rBC2LCN检测到的人类乳腺癌亚型和阶段。与rBC2LCN阴性乳腺癌细胞系相比，rBC2LCN阳性细胞表达更高水平的人表皮生长因子受体2（HER2）和上皮标记基因。重要的是，人乳腺癌组织的rBC2LCN组织化学染色证明了rBC2LCN在检测表达HER2但在生长早期没有广泛扩散的乳腺癌类型中的实用性。我们得出的结论是，rBC2LCN可能有潜力作为检测和鉴定和治疗早期HER2阳性乳腺癌的药物递送工具。

更新日期：2020-05-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11